Altimmune (ALT) EBIT (2010 - 2026)
Altimmune (ALT) reported EBIT of -$24.2 million for Q1 2026, down 11.13% year-over-year from -$27.3 million in Q1 2025, and up 16.09% on a QoQ basis from -$28.9 million in Q4 2025.
Altimmune (ALT) has 17 years of EBIT data on file, last reported at -$24.2 million in Q1 2026.
- Quarterly EBIT fell 11.13% year-over-year to -$24.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$96.9 million (up 1.3% YoY) and the FY2025 annual result came in at -$94.5 million, up 8.42% from the prior year.
- EBIT rose to -$24.2 million in Q1 2026 per ALT's latest filing, from -$28.9 million in the prior quarter.
- Across five years, EBIT topped out at -$18.0 million in Q2 2023 and bottomed at -$33.6 million in Q4 2023.
- The 5-year median for EBIT is -$23.1 million (2022), against an average of -$23.9 million.
- Peak annual rise in EBIT reached 26.04% in 2024, while the deepest fall reached 48.53% in 2024.
- Tracing ALT's EBIT over 5 years: stood at -$23.1 million in 2022, then plunged by 45.59% to -$33.6 million in 2023, then rose by 26.04% to -$24.9 million in 2024, then retreated by 16.19% to -$28.9 million in 2025, then increased by 16.09% to -$24.2 million in 2026.
- Per Business Quant, the three latest ALT EBIT figures stand at -$24.2 million (Q1 2026), -$28.9 million (Q4 2025), and -$20.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Altimmune | 379.61 Mn | 379.61 Mn | - | -24.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -24.24 Mn |
| Dec 31, 2025 | -28.89 Mn |
| Sep 30, 2025 | -20.86 Mn |
| Jun 30, 2025 | -22.92 Mn |
| Mar 31, 2025 | -21.82 Mn |
| Dec 31, 2024 | -24.87 Mn |
| Sep 30, 2024 | -24.77 Mn |
| Jun 30, 2024 | -26.75 Mn |
| Mar 31, 2024 | -26.79 Mn |
| Dec 31, 2023 | -33.62 Mn |
| Sep 30, 2023 | -22.54 Mn |
| Jun 30, 2023 | -18.01 Mn |
| Mar 31, 2023 | -21.76 Mn |
| Dec 31, 2022 | -23.09 Mn |
| Sep 30, 2022 | -24.75 Mn |
| Jun 30, 2022 | -20.40 Mn |
| Mar 31, 2022 | -19.50 Mn |
| Dec 31, 2021 | -23.99 Mn |
| Sep 30, 2021 | -33.20 Mn |
| Jun 30, 2021 | -24.86 Mn |
| Mar 31, 2021 | -14.86 Mn |
| Dec 31, 2020 | -10.75 Mn |
| Sep 30, 2020 | -18.32 Mn |
| Jun 30, 2020 | -18.42 Mn |
| Mar 31, 2020 | -7.31 Mn |
| Dec 31, 2019 | -4.31 Mn |
| Sep 30, 2019 | -11.27 Mn |
| Jun 30, 2019 | -3.55 Mn |
| Mar 31, 2019 | -2.33 Mn |
| Dec 31, 2018 | -27.35 Mn |
| Sep 30, 2018 | -4.06 Mn |
| Jun 30, 2018 | -5.44 Mn |
| Mar 31, 2018 | -5.99 Mn |
| Dec 31, 2017 | -12.56 Mn |
| Sep 30, 2017 | -30.95 Mn |
| Jun 30, 2017 | -4.01 Mn |
| Mar 31, 2017 | -4.52 Mn |
| Dec 31, 2016 | -5.51 Mn |
| Sep 30, 2016 | -4.79 Mn |
| Jun 30, 2016 | -1.60 Mn |
| Mar 31, 2016 | -1.25 Mn |
| Dec 31, 2015 | -940,469.00 |
| Sep 30, 2015 | -1.66 Mn |
| Jun 30, 2015 | -1.96 Mn |
| Mar 31, 2015 | 1.16 Mn |
| Dec 31, 2014 | -2.62 Mn |
| Sep 30, 2014 | -4.00 Mn |
| Jun 30, 2014 | -1.17 Mn |
| Mar 31, 2014 | -2.40 Mn |
| Dec 31, 2013 | -5.07 Mn |
| Sep 30, 2013 | -3.20 Mn |
| Jun 30, 2013 | -1.48 Mn |
| Mar 31, 2013 | -1.09 Mn |
| Dec 31, 2012 | -1.43 Mn |
| Sep 30, 2012 | -1.79 Mn |
| Jun 30, 2012 | -1.46 Mn |
| Mar 31, 2012 | -1.59 Mn |
| Dec 31, 2011 | -1.08 Mn |
| Sep 30, 2011 | -3.02 Mn |
| Jun 30, 2011 | -3.08 Mn |
| Mar 31, 2011 | -4.54 Mn |
| Dec 31, 2010 | -7.25 Mn |
| Sep 30, 2010 | -3.36 Mn |
| Jun 30, 2010 | -5.54 Mn |